- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 11: Two Paradigms Being Presented in Medical Oncology
Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.
Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.
He used the example of prophylactic mastectomy. Performing one on every 20-year-old woman would decrease breast cancer mortality by 95% over the next decade, but it’s not an acceptable course of action unless someone has a high chance of developing cancer or dying from it.
“We need to be really, really careful about these tests because unacceptable approaches become acceptable if you provide data,” he said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
